Pulmonary arterial hypertension (PAH) is a rare, progressive, and often fatal cardiopulmonary condition characterized by pulmonary vascular remodeling and progressive narrowing, leading to increased ...

GLP-tox study reinforces favorable safety profile of Tiprelestat Phase II Study in Pulmonary Arterial Hypertension (PAH) to be initiated ...

Winrevair yielded significant and meaningful clinical benefits for patients with combined post- and precapillary pulmonary ...

A recent publication in the International Journal of Cardiology, Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary ...

A relatively new therapy used to treat pulmonary arterial hypertension in those with mild to moderate disease was found to be effective at preventing death in those with more advanced disease. Results ...

The phase 2 Cadence trial met its primary endpoint, showing that Winrevair improved the ability of blood to transition through the lungs to the heart in patients with combined post- and precapillary ...

In March, we reported on back-to-back FDA approvals for two treatments in pulmonary arterial hypertension (PAH). In this ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Pulmonary hypertension in and of itself is ...

Learn the causes, symptoms, and treatment options for pulmonary hypertension—a serious condition affecting blood pressure in ...

A relatively new therapy used to treat pulmonary arterial hypertension in those with mild to moderate disease was found to be effective at preventing death in those with more advanced disease. Results ...

Liquidia Corporation has announced that its inhalation powder YUTREPIA™ (treprostinil) is now available for prescription at specialty pharmacies, following FDA approval on May 23, 2025, for treating ...